Children conceived using assisted reproductive technology do not have an increased cancer risk relative to either the general population or naturally conceived children of women with impaired fertility, shows a Dutch study with a long follow-up.
Women with rheumatoid arthritis have a significantly lower chance of having a live birth following assisted reproductive technology treatment than women without RA, researchers report in the Annals of the Rheumatic Diseases.
Women with polycystic ovary syndrome may have an increased likelihood for developing cancer, although the excess risk appears to be primarily restricted to those who are premenopausal, indicates a population-based study.
Progression-free survival is significantly improved with the use of maintenance olaparib in women with newly diagnosed FIGO stage III or IV ovarian cancer and a BRCA1/2 mutation, shows the placebo-controlled SOLO1 trial.
The use of hormonal contraceptives just before and during pregnancy may significantly increase the risk for childhood non-lymphoid leukemia, Danish researchers report.
Women with rheumatoid arthritis and those with juvenile idiopathic arthritis have a significantly elevated risk for preterm delivery, according to a prospective cohort study published in Arthritis Care & Research.
US researchers have found evidence to support catch-up vaccination against the human papillomavirus in women given their first dose in older adolescence.
Oral etoposide plus apatinib is associated with a good objective response rate and manageable toxicity in heavily pretreated Chinese women with platinum-resistant or refractory ovarian cancer, according to results of the phase II AEROC study.
The birth rate for women who are relapse-free after treatment for Hodgkin lymphoma has risen in recent years, becoming comparable with that of the general population regardless of disease stage or treatment.
Women who undergo assisted reproduction may be at increased risk for in situ breast cancer, and invasive and borderline ovarian tumors, show results of a large, population-based study.
Women with inflammatory arthritis who discontinue tumor necrosis factor inhibitor therapy during pregnancy may be at increased risk for flare, researchers report.
Cisplatin chemoradiotherapy significantly delays disease recurrence and improves survival compared with radiotherapy alone in women with stage IIIB squamous cell carcinoma of the cervix, phase III study data show.
Temporary ovarian suppression with a gonadotropin-releasing hormone analog alongside neoadjuvant or adjuvant chemotherapy could help preserve ovarian function and fertility in premenopausal women with early-stage breast cancer, shows a pooled analysis.
Maintenance therapy with olaparib, given in the newer tablet formulation, significantly improves progression-free survival compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation, phase III trial data show.
Women with hepatitis B virus infection prior to becoming pregnant are significantly more likely to have a preterm birth than those without HBV, shows an analysis of a Chinese population-based cohort.
Women with a juvenile idiopathic arthritis diagnosis are at increased risk for both maternal and infant complications during pregnancy and birth, show data from a nationwide Swedish study.
Adverse birth outcomes, specifically preterm births and infants with low birth weight, are more likely among adolescent and young adult cancer survivors than women without cancer, a US study shows.
Two independent studies shed light on the effects of pregnancy during cancer, one finding that pregnancy does not adversely affect the survival of women with breast cancer and the other showing an association between maternal cancer and an increased risk for stillbirth and neonatal mortality.
Predicting adverse motor and cognitive outcomes in preterm neonates with white matter injury requires the mapping of both lesion volume and location, suggests a magnetic resonance imaging study.
The US Preventive Services Task Force has reaffirmed its 2009 recommendation that women who are planning or capable of pregnancy should take a daily supplement containing 400 µg to 800 µg of folic acid for the prevention of neural tube defects.